Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/1998

01-03-1998 | ORIGINAL ARTICLE

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

Authors: Claire A. Coggins, Gertrude B. Elion, Peter J. Houghton, C. Bradley Hare, O. Michael Colvin, Darell D. Bigner, Henry S. Friedman, Steve Keir

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/1998

Login to get access
Metadata
Title
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents
Authors
Claire A. Coggins
Gertrude B. Elion
Peter J. Houghton
C. Bradley Hare
O. Michael Colvin
Darell D. Bigner
Henry S. Friedman
Steve Keir
Publication date
01-03-1998
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/1998
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050771

Other articles of this Issue 6/1998

Cancer Chemotherapy and Pharmacology 6/1998 Go to the issue

ORIGINAL ARTICLE

Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer

ORIGINAL ARTICLE

Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line

ORIGINAL ARTICLE

Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2′-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin

ORIGINAL ARTICLE

Practical implementation of a modified continual reassessment method for dose-finding trials

ORIGINAL ARTICLE

Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models

ORIGINAL ARTICLE

Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits